Finja Jockenhöfer

Finja Jockenhöfer

Auto-generated profile, based on publicly available information

Finja Jockenhöfer

Department of Dermatology, Venereology and Allergology, University Hospital of Essen, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
FJF. Jockenhöfer
F. Jockenhöfer
UWU. Wollina
U. Wollina
KSK.A. Salva
K.A. Salva
SBSven Benson
Sven Benson
JDJ. Dissemond
J. Dissemond

9 December 2019 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Open access
PDF file
FJFinja Jockenhöfer
Finja Jockenhöfer
CKChristopher Knust
Christopher Knust
SBSven Benson
Sven Benson
MSManfred Schedlowski
Manfred Schedlowski
JDJoachim Dissemond
Joachim Dissemond
Summary: Introduction: Placebo effects are used in the treatment of various medical conditions. To date, there is little scientific data in this regard as it relates to skin diseases in general and hardly any data with respect to wound healing in particular.Material and methods: In a prospective randomized controlled trial, patients with chronic venous leg ulcers were observed for a period of 14 weeks. The objective was to investigate whether raising patients’ expectations with regard to a novel wound treatment might have an effect on wound healing processes as well as wound‐related quality of life, anxiety, depression and pain.Results: Overall, 20 patients were included in the trial. They were stratified based on gender and randomized to either the intervention (IG) or the control group (CG). In both groups, the wound area decreased significantly over the course of the observation period. Unlike patients in the CG, those in the IG experienced significant improvement in wound‐related quality of life (wound‐QoL) in terms of both the overall score and the various subscales. Neither group showed significant changes with respect to pain, anxiety and depression.Conclusions: Our study is the first to show that – merely by raising patients’ expectations for a novel treatment – placebo effects can significantly improve quality of life in patients with chronic venous leg ulcers. In the future, our findings should be integrated into the development of treatment concepts for patients with chronic wounds and should be investigated in larger cohorts.

1 July 2022 in Vasa
Verified
Journal Article
Closed access
FRFinja Reinboldt-Jockenhöfer
Finja Reinboldt-Jockenhöfer
JTJürg Traber
Jürg Traber
LHLiezl Ingrid Holzer
Liezl Ingrid Holzer
AWAlexander von Weymarn
Alexander von Weymarn
JDJoachim Dissemond
Joachim Dissemond
SDStefan Duewell
Stefan Duewell
Summary: Background: The treatment success of catheter-based ovarian vein embolization due to peripheral varicose veins and ovarian vein reflux (OVR) should be investigated in this clinical investagtion. Patients and methods: For this study, 95 female patients were identified over a 5-year period (beginning of 2006 to end of 2011) after catheter-based coil (+/- chemical) embolization of the ovarian vein due to peripheral primary or recurrent varicose veins and proven reflux in the ovarian vein. Treatment success was retrospectively assessed in 2014 by means of a structured telephone interview (n=60), clinical examination (n=56), duplex ultrasound (n=56) and magnetic resonance imaging (n=51) in patients who were willing to participate in the study. Results: After an average of 51.9 months, 95.2% of the 60 included patients were diagnosed with recurrent varicose veins by duplex sonography and 88.1% by clinical examination. In 15.2%, a new intervention was required due to clinical symptoms. The median recurrence-free time was 47.0±5.5 months. A significant improvement by therapy was reported for all subjective symptoms in both pelvis and legs. No significant correlation between radiological findings and complaints or between radiological findings and clinical recurrence was found. Conclusions: The medical history of female patients with peripheral varicose veins should obligatorily include the question of symptoms in the pelvis. An appropriate diagnostic should follow in order to prevent a possible overlook of a pelvic leak point. Only then an individually adapted therapy for symptom relief is possible. Catheter-based ovarian vein embolization is one optional safe procedure that leads to significant improvement of subjective symptoms but does not necessarily prevent recurrent varicose veins.

15 December 2017 in Gut
Verified
Journal Article
Closed access
PDF file
FJFinja Jockenhöfer
Finja Jockenhöfer
TSTobias T Schimming
Tobias T Schimming
JSJörg Schaller
Jörg Schaller
JMJürgen Moege
Jürgen Moege
ELElisabeth Livingstone
Elisabeth Livingstone
ARAlexander Rösch
Alexander Rösch
Clinical presentation: A 77-year-old man presented to our skin cancer centre with various cutaneous tumours occurring in 2006–2017. Histopathology showed a ‘hidradenocarcinoma’ on the left upper back (2006) and a sebaceous adenoma (figure 1) on the left shoulder (2011). In 2017, he developed a sebaceous carcinoma on the middle upper back, which manifested as a slowly enlarging, asymptomatic nodule. Medical history was significant for curative resection of colorectal cancer in 1988. Figure 1 Clinical appearance of the sebaceous adenoma on the patient’s left shoulder in 2011. The most recent lesion was subjected to extensive immunohistochemical assessment. The neoplastic cells were positive for cytokeratin 5/6, cytokeratin 7, cluster of differentiation antigen 10, adipophilin, androgen receptor, epithelial membrane antigen, KI67 antigen, MLH1 and PMS2, but stained negative for gross cystic disease fluid protein 15, prostate-specific antigen, carbohydrate antigen 19/9, CDX2 protein, hepatocyte-specific antigen, carcinoembryonic antigen, cluster of differentiation antigen 117 and cytokeratin 19. Given the variety of histological manifestations of the patient’s skin neoplasms, further studies were performed. They revealed positive nuclear expression signals for MLH1, MSH6 and PMS2, whereas MSH2 expression was absent in almost all tumour cells (figure 2). Positron emission tomography (PET)/CT and colonoscopy did not detect any pathological findings. However, molecular genetic analysis of peripheral blood showed a heterozygous deletion of exon 7 of the MSH2 gene. Subsequently, several family members tested positive for MSH2 mutations and underwent genetic counselling. Figure 2 (A–D) Histopathological images of the patient’s most recent lesion (diaminobenzidine, original magnification, ×100). The tumour cells demonstrated strong nuclear positivity for MLH1 (A) and PMS2 (B), but were essentially negative for MSH6 (C) and MSH2 (D). Question: What is your diagnosis?: Diagnosis: Muir-Torre syndrome (MTS).

21 May 2026 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Open access
ODOlivia Danneil
Olivia Danneil
JDJoachim Dissemond
Joachim Dissemond
FRFinja Reinboldt‐Jockenhöfer
Finja Reinboldt‐Jockenhöfer